Combination of non-specific immunopotentiation with Corynebacterium liquefaciens and chemotherapy in tumor-bearing mice.
The effect of combining chemotherapeutics (Mitomycin-C, cyclophosphamide, or 5-fluorouracil) and immunopotentiator (anaeobic Corynebacterium liquefaciens) against Ehrlich ascites carcinoma in mice was examined. Mitomycin-C and cyclophosphamide were given intraperitoneally 2 days after the inoculation of tumor cells. 5-Fluorouracil was administered intraperitoneally for 7 consecutive days beginning from the second day after inoculation of tumor cells. C. liquefaciens was given intraperitoneally in various time regimens before or after the drug. The best prolongation of survival was observed when C. liquefaciens was given after the administration of Mitomycin-C or cyclophosphamide but no effect was seen in the combination of 5-fluorouracil and C. liquefaciens. These results suggest that non-specific active immunotherapy using C. liquefaciens may be a valuable adjunct to the conventional cytocidal anticnacer chemotherapy with agents such as Mitomycin-C or cyclophosphamide and the most important variable seems to be the time at which the immunopotentiator is given during the therapy.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000628:therapy*; D003352:Corynebacterium / Q000276:immunology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D051379:Mice; D008937:Mitomycins / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001428:Bacterial Vaccines; D008937:Mitomycins; D003520:Cyclophosphamide; D005472:Fluorouracil